Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Sutro Biopharma (STRO) has disclosed Long-Term Investments for 4 consecutive years, with $20.7 million as the latest value for Q1 2022.

  • Quarterly Long-Term Investments fell 72.25% to $20.7 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $20.7 million through Mar 2022, down 72.25% year-over-year, with the annual reading at $68.8 million for FY2021, N/A changed from the prior year.
  • Long-Term Investments hit $20.7 million in Q1 2022 for Sutro Biopharma, down from $68.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $74.6 million in Q1 2021 to a low of $5.6 million in Q2 2020.
  • Historically, Long-Term Investments has averaged $34.3 million across 4 years, with a median of $20.7 million in 2022.
  • Biggest five-year swings in Long-Term Investments: soared 971.54% in 2021 and later tumbled 72.25% in 2022.
  • Year by year, Long-Term Investments stood at $15.6 million in 2019, then tumbled by 64.12% to $5.6 million in 2020, then skyrocketed by 1128.57% to $68.8 million in 2021, then tumbled by 69.91% to $20.7 million in 2022.
  • Business Quant data shows Long-Term Investments for STRO at $20.7 million in Q1 2022, $68.8 million in Q4 2021, and $64.3 million in Q3 2021.